<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - LORAZEPAM</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>LORAZEPAM</h1>

        <p><a href="../drugClass/PHP34584.html">BENZODIAZEPINES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term use in anxiety</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;4 mg daily in divided doses, for debilitated patients, use elderly dose.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                0.5&#8211;2 mg daily in divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term use in insomnia associated with anxiety</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;2 mg daily, to be taken at bedtime.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute panic attacks</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                25&#8211;30 micrograms/kg every 6 hours if required; usual dose 1.5&#8211;2.5 mg every 6 hours if required, intravenous injection to be administered into a large vein, only use intramuscular route when oral and intravenous routes not possible.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Conscious sedation for procedures</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;3 mg, to be taken the night before operation; 2&#8211;4 mg, to be taken 1&#8211;2 hours before operation.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 micrograms/kg, to be administered 30&#8211;45 minutes before operation.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 micrograms/kg, to be administered 60&#8211;90 minutes before operation.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;3 mg, to be taken the night before operation; 2&#8211;4 mg, to be taken 1&#8211;2 hours before operation.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 micrograms/kg, to be administered 30&#8211;45 minutes before operation.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 micrograms/kg, to be administered 60&#8211;90 minutes before operation.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Status epilepticus</span>,
                <span class="indication">Febrile convulsions</span>,
                <span class="indication">Convulsions caused by poisoning</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                4 mg for 1 dose, then 4 mg after 10 minutes if required for 1 dose, to be administered into a large vein.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                100 micrograms/kg (max. per dose 4 mg) for 1 dose, then 100 micrograms/kg after 10 minutes (max. per dose 4 mg) if required for 1 dose, to be administered into a large vein.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                4 mg for 1 dose, then 4 mg after 10 minutes if required for 1 dose, to be administered into a large vein.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.</p><p>All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Start with smaller initial doses or reduce dose.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In adults</h3>
              <p>If treatment is necessary, benzodiazepines with shorter half-lives are safer.</p>
            </section>
            <section class="generalInformation">
              <p>Can precipitate coma.</p><p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Start with small doses in severe impairment.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid injections containing benzyl alcohol in neonates</li>
            <li><strong>adults:</strong> chronic psychosis in adults</li>
            <li>CNS depression</li>
            <li>compromised airway</li>
            <li>hyperkinesis</li>
            <li><strong>adults:</strong> not for use alone to treat depression (or anxiety associated with depression) in adults</li>
            <li>obsessional states</li>
            <li>phobic states</li>
            <li>respiratory depression</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Amnesia, ataxia in children, ataxia (especially in the elderly) in adults, confusion in children, confusion (especially in the elderly) in adults, dependence, drowsiness the next day, lightheadedness the next day, muscle weakness, paradoxical increase in aggression,
              </p>
              <p>
                <strong>uncommon:</strong> Changes in libido in adults, dizziness, dysarthria, gastro-intestinal disturbances, gynaecomastia, headache in adults, hypotension in adults, incontinence, salivation changes, slurred speech in adults, tremor, urinary retention in adults, vertigo in adults, visual disturbances,
              </p>
              <p>
                <strong>rare:</strong> Apnoea, blood disorders, changes in libido in children, headache in children, hypotension in children, jaundice, respiratory depression, skin reactions, urinary retention in children, vertigo in children,
              </p>
              <p>
                <strong>notKnown:</strong> Delusions in children, excitement in children, hallucinations in children, irritability in children, marked respiratory depression, particularly with high dose and intravenous use (facilities for its treatment are essential), pain (on intravenous injection), psychosis in children, restlessness in children, thrombophlebitis (on intravenous injection),
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous injection</i>, dilute with an equal volume of Sodium Chloride 0.9% (for neonates, dilute injection solution to a concentration of 100&#8239;micrograms/mL). Give over 3&#8211;5 minutes; max. rate 50&#8239;micrograms/ kg over 3 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For intramuscular injection, solution for injection should be diluted with an equal volume of water for injections or sodium chloride 0.9% (but only use when oral and intravenous routes not possible).</p><p>For slow intravenous injection, solution for injection should preferably be diluted with an equal volume of water for injections or sodium chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to <b>at least 24 hours</b> after administration. Responsible persons should be available to take patients home afterwards. The dangers of taking <b>alcohol</b> should be emphasised.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Anaesthesia</h3>
              <p>Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Muscle weakness
          </li>
          <li>
            organic brain changes
          </li>
          <li>
            parenteral administration
          </li>
          <li>
            personality disorder (within the fearful group&#8212;dependent, avoidant, obsessive-compulsive) may increase risk of dependence
          </li>
        </ul>
        <ul>
          <li>
              <strong>With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use:</strong>
            <p>When given parenterally, facilities for managing respiratory depression with mechanical ventilation must be available. Close observation required until full recovery from sedation.</p>
          </li>
          <li>
            <p>A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.</p>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in febrile convulsions.</p><p>Not licensed for use in convulsions caused by poisoning.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Not licensed for use as premedication in children under 12 years.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Not licensed for use as premedication in children under 5 years.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of LORAZEPAM</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,
            oral solution,
            oral suspension,

            <div id="PHP75096"><a href="../medicinalForm/PHP75096.html" data-target="#PHP75096" data-action="load">Tablet</a></div>
            <div id="PHP75111"><a href="../medicinalForm/PHP75111.html" data-target="#PHP75111" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
